A report released today by Panmure Gordon about Sphere Medical Holding PLC (LON:SPHR) maintains the target price at 17.00GBX
- Updated: September 29, 2016
Sphere Medical Holding PLC (LON:SPHR) had its target price hold steady to 17.00GBX by Panmure Gordon in an issued report announced 9/30/2016. The latest target price indicates a potential upside of 0.45% from the company's previous stock close price.
On 9/22/2016, Panmure Gordon released a statement about Sphere Medical Holding PLC (LON:SPHR) maintained the target price at 17.00GBX that suggested an upside of 0.36%.
Only yesterday Sphere Medical Holding PLC (LON:SPHR) traded -0.04% lower at 11.75GBX. The company’s 50-day moving average is 11.63GBX and its 200-day moving average is 11.09GBX. The last stock price is up 3.62% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Volume of trade was up over the average, with 96,042 shares of SPHR changing hands over the typical 88,223
Recent Performance Chart
Sphere Medical Holding PLC has a with a one year low of 6.00GBX and a one year high of 15.00GBX Sphere Medical Holding PLC’s market capitalization is currently 0 GBX.
General Company Details For Sphere Medical Holding PLC (LON:SPHR)
Sphere Medical Holding plc is engaged in the development of medical monitoring and diagnostic equipment. The Company operates through medical devices segment. The Company is engaged in the manufacture and sale of products within the medical device area. The Company's products include Proxima and Pelorus. Proxima is a patient-connected blood gas and electrolyte solution for managing patient pathways. Proxima is an in-line patient arterial blood analyzer, which supports measurements at critical times. Its products are used in intensive care (ICU) and operating room (OR) environments to provide physicians with data to help them make clinical decisions for their patients. Its products and systems help in a range of medical situations, including blood gas monitoring and analysis, propofol sedation and total intravenous anesthesia (TIVA). The Company has operations in the United Kingdom, Germany, the Netherlands and Belgium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.